RICOS BIOLOGY Journal
2026, Vol. 4, No. 4, 21-24
doi: https://doi.org/10.33687/ricosbiol.04.02.116

Review article

Beyond the Pair: A Hypothesis on Multi-Antibiotic Synergy for Optimized Bacterial Infection Control

*Abouelhag H. A.**

Microbiology and Immunology Dept., National Research Centre, Dokki, Egypt, 12622.

Received: 08-04-2026 **Accepted:** 22-04-2026 **Published online:** 30-04-2026
DOI: https://doi.org/10.33687/ricosbiol.04.04.116

Abstract

The escalating crisis of antimicrobial resistance (AMR) poses an existential threat to modern medicine, necessitating innovative strategies beyond conventional single and dual-antibiotic therapies. This review article hypothesizes that employing more than two antibiotics concurrently may offer a superior paradigm for treating bacterial infections. We propose that a multi-antibiotic cocktail, featuring agents with distinct and overlapping modes of action (MoA), can simultaneously target multiple critical bacterial pathways (e.g., cell wall synthesis, protein synthesis, folate metabolism, and nucleic acid replication). This polypharmacological approach is theorized to achieve potent synergistic effects, enabling a significant reduction in the effective dose of each individual antibiotic. Consequently, lower doses could diminish dose-dependent toxicity, reduce selective pressure for resistance mutations, and potentially lower overall treatment costs by shortening therapy duration and preventing treatment failures from resistant strains. This review synthesizes theoretical foundations, preliminary evidence from combination therapy, and pharmacokinetic/pharmacodynamic (PK/PD) principles to support this hypothesis. We critically analyze potential risks, including antagonism and toxicity, and propose a roadmap for future research using *in vitro* synergy models and *in vivo* validation. We conclude that while challenging, the strategic use of multi-antibiotic (≥3 agents) regimens warrants rigorous investigation as a promising weapon against the rising tide of AMR.

Keywords:
Multi-antibiotic therapy, antimicrobial resistance (AMR), synergistic combinations, polypharmacology, dose reduction, side effect mitigation, bacterial infection, combination therapy, mode of action.

I. Introduction

The discovery of antibiotics revolutionized medicine, turning once-fatal bacterial infections into manageable ailments. However, this golden age is waning. The relentless evolutionary pressure of antimicrobial selection has spawned multidrug-resistant (MDR) and extensively drug-resistant (XDR) "superbugs," such as methicillin-resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant *Enterobacteriaceae* (CRE), and multidrug-resistant *Pseudomonas aeruginosa* (World Health Organization, 2017). Conventional treatment strategies primarily rely on monotherapy or, in severe cases, dual-antibiotic therapy (e.g., a beta-lactam combined with an aminoglycoside). While dual therapy offers advantages over monotherapy, including broader coverage and delayed resistance, its efficacy against robust, biofilm-forming, or rapidly mutating pathogens is increasingly limited (Torella et al., 2010).

A fundamental limitation of using one or two antibiotics is the finite number of selective targets. Pathogens can often acquire resistance via a single or double mutation (e.g., efflux pump upregulation, target modification, enzymatic degradation) that simultaneously compromises multiple drugs, especially if those drugs share similar resistance mechanisms (Fischbach, 2011). This review advances a more radical hypothesis: that a rationally designed combination of three or more antibiotics, each with a distinct primary mode of action (MoA), could overcome many limitations of current therapies. By saturating the bacterial cell with attacks on multiple essential systems, this strategy could lower the effective individual doses, drastically suppress the emergence of resistant mutants, and ultimately prove more cost-effective by preventing prolonged or expensive treatment failures.

1. The Hypothesis: Multi-Target Saturation Therapy

The central hypothesis of this review is as follows:

In the treatment of susceptible and moderately resistant bacterial infections, the concurrent use of three or more antibiotics, each operating via a distinct and non-overlapping primary mode of action, will result in superior clinical outcomes compared to mono- or dual-therapy. This superiority will be evidenced by (1) enhanced bactericidal synergy allowing for (2) a significant reduction in the individual effective dose of each antibiotic, which will (3) decrease the selective pressure for the development of antimicrobial resistance, (4) reduce the dose-dependent side effects of individual antibiotics, and (5) lower the overall economic cost of treatment by reducing length of therapy, ICU admission, and failure-related re-treatments.

Corresponding author: *Abouelhag H. A.*
ha.elhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2026, Vol. 4, No. 4, 21-24
doi: https://doi.org/10.33687/ricosbiol.04.02.116

This hypothesis is grounded in the principles of polypharmacology and systems biology, where attacking a complex biological network (the bacterial metabolon) at multiple vulnerable nodes is more robust and less prone to adaptive resistance than attacking one or two nodes (Csermely et al., 2005).

2. Theoretical Framework and Proposed Mechanisms

2.1. Complementary and Synergistic Modes of Action

The proposed advantage stems from covering the key "Achilles' heels" of the bacterial cell. A hypothetical three-drug regimen could target:

- **Cell Wall Synthesis:** (e.g., Vancomycin, β-lactams like Meropenem).
- **Protein Synthesis (30S subunit):** (e.g., Amikacin, Tetracycline).
- **Folate Metabolism:** (e.g., Trimethoprim, Sulfamethoxazole).
- **Nucleic Acid Synthesis:** (e.g., Ciprofloxacin, Rifampin).

By simultaneously inhibiting cell wall integrity, protein production, and folate synthesis, the bacterium cannot compensate for failure in one pathway by upregulating another, as it might with a single drug (Yeh et al., 2009). This multi-target engagement produces **supra-additive (synergistic) effects**, where the combined inhibitory concentration is far less than the sum of the individual minimal inhibitory concentrations (MICs) (Chou, 2006).

2.2. Reduction of Dose-Dependent Side Effects

A major advantage of using more than two antibiotics is the ability to reduce the dose of any single antibiotic that is otherwise associated with severe adverse effects at high concentrations. Many antibiotics exhibit dose-dependent toxicities: aminoglycosides cause nephrotoxicity and ototoxicity, vancomycin can lead to red man syndrome and renal impairment, and colistin is notorious for neurotoxicity and nephrotoxicity. When three or more agents are combined synergistically, each can be administered at a fraction of its usual therapeutic dose while still achieving bactericidal activity. This reduction directly lowers the peak serum and tissue concentrations of each drug, thereby decreasing the incidence and severity of their individual side effects. For example, a triple regimen containing a low-dose aminoglycoside would carry a substantially lower risk of irreversible hearing loss compared to standard monotherapy, while still contributing to the overall antibacterial effect (Drusano, 2004). Thus, multi-antibiotic synergy not only improves efficacy but also expands the therapeutic window of toxic but otherwise potent drugs.

2.3. Minimization of Individual Antibiotic Dose Required for Efficacy

Closely related to side effect reduction is the principle of dose minimization. When two or more antibiotics with different modes of action are used together, the required effective dose of each individual agent drops significantly. This phenomenon is quantified by the fractional inhibitory concentration index (FICI). In a true synergistic interaction (FICI < 0.5), the combination may achieve bacterial killing at concentrations as low as one-quarter or one-eighth of the MIC of each drug alone (Odds, 2003). Extending this to three drugs, the potential for dose reduction becomes even more pronounced. For instance, if Drug A alone requires 8 µg/mL to inhibit growth, in the presence of Drugs B and C (each at sub-inhibitory concentrations), Drug A might become effective at only 1–2 µg/mL. Such minimization has profound clinical implications: it allows the use of antibiotics that would otherwise be ineffective due to toxicity or cost, and it reduces the total antibiotic burden on the patient's microbiome and organ systems. Moreover, lower doses slow the depletion of antibiotic reserves, which is particularly relevant for agents in short supply or with narrow therapeutic indices.

2.4. The Resistance Suppression Paradigm

The evolution of resistance is a numbers game. The probability of a bacterial population containing a mutant resistant to a single drug is approximately 1 in 10^8. The probability of a mutant resistant to two different drugs is the product of their individual mutation frequencies, roughly 1 in 10^{16}. For three drugs with distinct MoAs, the probability drops to 1 in 10^{24} (Borisy et al., 2003). A bacterial cell would need to simultaneously acquire three independent, non-compensatory resistance mutations—an astronomically rare event under normal selective pressure. Furthermore, the lower individual doses reduce the selective gradient, preventing the outgrowth of low-level resistant subpopulations (the "mutant selection window") (Zhao & Drlica, 2001).

3. Evaluating the Hypothesis: Evidence and Challenges

3.1. Preliminary and Analogous Evidence

While not standard, examples of triple therapy exist:

- **Tuberculosis (TB):** The standard of care for drug-susceptible TB is a 6-month regimen of four drugs (Isoniazid, Rifampin, Ethambutol, Pyrazinamide) (World Health Organization, 2019). This is the strongest real-world validation of the hypothesis. The multi-drug cocktail is essential to cure and prevent relapse, precisely due to synergy and resistance suppression.
- **Cystic Fibrosis (CF) with *P. aeruginosa*:** Triple combinations (e.g., Ceftazidime + Tobramycin + Ciprofloxacin) have shown enhanced biofilm eradication compared to dual therapy in *in vitro* models (Tricoli et al., 2017).
- **Helicobacter pylori:** Triple therapy (a proton pump inhibitor + Amoxicillin + Clarithromycin or Metronidazole) was the longstanding gold standard.

Corresponding author: *Abouelhag H. A.*
ha.elhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2026, Vol. 4, No. 4, 21-24
doi: https://doi.org/10.33687/ricosbiol.04.02.116

3.2. Potential Risks and Counterarguments (Critical Analysis)

- Antagonism: Not all combinations are synergistic. Some can be antagonistic (e.g., bacteriostatic + bactericidal combinations like Tetracycline + Penicillin can reduce killing efficacy). Careful *in vitro* checkerboard assays are required to identify supra-additive vs. antagonistic triads (Odds, 2003).
- **Toxicity and Adverse Events:** Using more drugs inherently increases the risk of adverse drug reactions (ADRs), allergic reactions, and drug-drug interactions. However, as argued in sections 3.2 and 3.3, the lower individual doses may offset this risk. Rigorous clinical trials are needed to establish the net benefit.
- **Microbiome Disruption:** Broad-spectrum triple therapy could cause severe dysbiosis, increasing the risk of *Clostridioides difficile* infection and secondary fungal infections. Narrow-spectrum triple therapy tailored to the pathogen is crucial.

Cost Paradox: While we hypothesize lower *total* treatment cost, the upfront pharmacy cost for three patent-protected or novel antibiotics may be higher. Cost-effectiveness analysis (CEA) must account for prevented ICU stays and failures.

4. Proposed Strategy for Clinical Implementation

To translate this hypothesis into practice, we propose a stepwise framework:

- **Rational Selection via Systems Biology:** Use computational models to predict synergistic triads based on complementary MoA and bacterial metabolic networks.
- **In Vitro Validation:** Perform high-throughput checkerboard synergy assays (e.g., 3D broth microdilution) against a panel of reference and MDR clinical isolates. Define synergy using the Fractional Inhibitory Concentration Index (FICI < 0.5) (Doern, 2014).
- **Resistance Prevention Studies:** Use hollow-fiber infection models (HFIM) to compare the mutant prevention concentration (MPC) and resistance emergence over time for mono-, dual-, and triple-therapy.
- **In Vivo Efficacy:** Validate in animal models (e.g., murine thigh infection or sepsis models) using humanized pharmacokinetic profiles.

Phased Clinical Trials: Begin with triple therapy for severe, hard-to-treat infections (e.g., carbapenem-resistant *Acinetobacter baumannii*) where current options are failing. Use adaptive trial designs to identify optimal dosing that minimizes toxicity.

Conclusion

The escalating AMR crisis demands a departure from reductionist, single-target thinking. The hypothesis that **three or more antibiotics are superior to one or two** is not merely speculative; it is supported by the success of TB therapy and sound population genetics. By attacking the bacterial cell on multiple fronts, multi-antibiotic synergy can lower individual doses, reduce dose-dependent side effects, and impose a near-insurmountable barrier to resistance evolution. While risks of antagonism and toxicity exist, these can be systematically managed through *in vitro* screening, PK/PD modeling, and careful trial design. We conclude that the paradigm of "more than two" is a scientifically rigorous, potentially cost-effective, and urgently needed frontier in the fight against bacterial infections. Future research should prioritize identifying safe, synergistic antibiotic triads for priority MDR pathogens.

References

Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehar, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., & Keith, C. T. (2003). Systematic discovery of multicomponent therapeutics. *Proceedings of the National Academy of Sciences, 100*(13), 7977–7982. https://doi.org/10.1073/pnas.1337088100

Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacological Reviews, 58*(3), 621–681. https://doi.org/10.1124/pr.58.3.10

Csermely, P., Ágoston, V., & Pongor, S. (2005). The efficiency of multi-target drugs: The network approach might help drug design. *Trends in Pharmacological Sciences, 26*(4), 178–182. https://doi.org/10.1016/j.tips.2005.02.007

Doern, C. D. (2014). When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. *Journal of Clinical Microbiology, 52*(12), 4124–4128. https://doi.org/10.1128/JCM.01121-14

Drusano, G. L. (2004). Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. *Nature Reviews Microbiology, 2*(4), 289–300. https://doi.org/10.1038/nrmicro862

Fischbach, M. A. (2011). Combination therapies for combating antimicrobial resistance. *Current Opinion in Microbiology, 14*(5), 519–523. https://doi.org/10.1016/j.mib.2011.08.003

Corresponding author: *Abouelhag H. A.*
ha.elhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2026, Vol. 4, No. 4, 21-24
doi: https://doi.org/10.33687/ricosbiol.04.02.116

Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. *Journal of Antimicrobial Chemotherapy, 52*(1), 1. https://doi.org/10.1093/jac/dkg301

Torella, J. P., Chait, R., & Kishony, R. (2010). Optimal drug synergy in antimicrobial treatments. *PLoS Computational Biology, 6*(6), e1000796. https://doi.org/10.1371/journal.pcbi.1000796

Tricoli, M., Nobile, C., & De Carvalho, C. C. C. R. (2017). Biofilm formation by *Pseudomonas aeruginosa* and its clinical implications. *Future Microbiology, 12*(15), 1381–1394. https://doi.org/10.2217/fmb-2017-0123

World Health Organization. (2017). *Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics*. WHO Press.

World Health Organization. (2019). *WHO consolidated guidelines on drug-resistant tuberculosis treatment*. WHO Press.

Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009). Drug interactions and the evolution of antibiotic resistance. *Nature Reviews Microbiology, 7*(6), 460–466. https://doi.org/10.1038/nrmicro2133

Zhao, X., & Drlica, K. (2001). Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. *Clinical Infectious Diseases, 33*(Supplement 3), S147–S156. https://doi.org/10.1086/321841

Data Availability Statement

No original datasets were generated for this review article. All cited data and findings are available within the original research publications referenced in the manuscript, accessible via the provided Digital Object Identifiers (DOIs) or through respective journal platforms.

Corresponding author: *Abouelhag H. A.*
ha.elhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net